CASE REPORT

Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report

Tobias Wienemann1†, Ann-Kristin Müller2†, Colin MacKenzie1, Carina Bielor2, Vivien Weyers2, Orhan Aktas2, Hans-Peter Hartung2 and David Kremer2*

Abstract

Background: Fingolimod (Gilenya®), a first-in-class sphingosine-1-phosphate receptor modulator is approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod-induced selective immunosuppression leads to an increased risk of opportunistic infections such as cryptococcosis. So far, a total of 8 cases of fingolimod-related cryptococcal meningoencephalitis have been published.

Case presentation: A 49-year-old female with relapsing-remitting multiple sclerosis presented with cephalgia, fever, confusion and generalized weakness. She had been on fingolimod therapy for the past 5.5 years. Clinical examination suggested meningoencephalitis and laboratory findings showed an IgG 2 deficiency. Initially no pathogen could be detected, but after 4 days Cryptococcus neoformans was found in the patient’s blood cultures leading to the diagnosis of cryptococcal meningoencephalitis. After antimycotic therapy, her symptoms improved and the patient was discharged.

Conclusion: MS patients on immunomodulatory therapy are at constant risk for opportunistic infections. Cephalgia, fever and generalized weakness in combination with fingolimod-induced lymphopenia should be considered a red flag for cryptococcosis.

Keywords: Cryptococcus, Meningoencephalitis, Multiple sclerosis, Fingolimod, Blood culture

Background

Fingolimod was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in 2010. By sequestering lymphocytes in lymphoid tissue it prevents their access to the central nervous system. This translates clinically to a reduction of relapse rate and radiologically to a decrease of lesion load and brain volume loss. However, peripheral lymphopenia is associated with an increased risk for opportunistic infections. The ubiquitous yeast Cryptococcus neoformans is a well-known cause of meningoencephalitis in immunocompromised people. Between 2015 and 2019 a total of 8 cases of cryptococcal meningoencephalitis in MS patients treated with fingolimod for 2–5 years have been reported [1–8]. We now describe a case of cryptococcal meningoencephalitis diagnosed 5.5 years after therapy initiation. This is the first case of a fingolimod-treated MS patient, in which cryptococci were initially detected in blood cultures leading to the correct diagnosis. In addition, our patient suffered from IgG2 deficiency which is

* Correspondence: david.kremer@med.uni-duesseldorf.de
† Tobias Wienemann and Ann-Kristin Müller contributed equally to this work.
2 Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
considered to be a crucial risk factor for the disease even in otherwise healthy individuals.

Case presentation
A 49-year-old Caucasian female with RRMS, who had been on fingolimod therapy for the past 5.5 years, presented with cephalgia, fever, confusion, coughing and generalized weakness. Prior to fingolimod, the patient had received therapies with interferons, natalizumab, mitoxantrone and rituximab which had all been discontinued due to persistent disease activity. Physical examination revealed mild temporal disorientation without new focal neurologic deficits or nuchal rigidity. Laboratory evaluation showed a normal total white cell count but a persistent absolute lymphopenia of as low as 0.09 × 1000/μl (normal range: 1.26–3.35 × 1000/μl). Chest X-ray and abdominal ultrasound yielded no signs of abnormalities. Multiple supra- and infratentorial non-gadolinium enhancing T2w lesions consistent with the diagnosis of MS were seen on MRI. There were no lesions suggestive of progressive multifocal leukoencephalopathy. Due to suspected meningoencephalitis blood cultures and a lumbar puncture were performed. Cerebrospinal fluid (CSF) analysis showed a lympho-monocytic pleocytosis of 54/μl (see Fig. 1b), elevated protein levels of 146 mg/dl and normal glucose and lactate levels. Microscopically, no pathogens were detectable. Intracranial pressure (ICP) was not elevated. The patient was diagnosed with meningoencephalitis of unclear aetiology and we started an empiric antibiotic regimen with ceftriaxone, ampicillin and acyclovir. Fingolimod therapy was stopped. CSF-PCR results for herpes and JC virus were negative and the patient remained clinically stable. Four days after admission we detected yeast-like formations in a gram stain of an aerobic blood culture bottle whereas the CSF cultures showed no signs of growth. Due to the unusual staining (Fig. 1c and d) the suspicion of Cryptococcus infection was raised. A lateral flow immunoassay (IMMY™) for cryptococcal antigen on the original CSF sample showed a positive antigen titre of 1:160. Sub-culture of the positive blood culture and CSF cultures demonstrated growth of Cryptococcus neoformans. As a result, 4 days after admission cryptococcal meningoencephalitis was diagnosed. Antimycotic susceptibility testing was conducted by microdilution. The German National Reference Centre for Invasive Fungal Infections verified the results and identified the species Cryptococcus neoformans var. grubii (serotype A) [9]. Antimycotic treatment with intravenous liposomal amphotericin B and oral fluconazole was begun. On subsequent interrogation we elicited that the patient owned a birdhouse, which she cleaned regularly. Since the
pulmonary tract is the common portal of entry for Cryptococcus and due to the initial respiratory symptoms, we performed a chest CT scan that revealed pulmonary lesions compatible with cryptococcosis (Fig. 1a). As cryptococcus infections usually occur in severely immunocompromised individuals and since previously only 8 cases in fingolimod-treated MS patients had been reported, we performed an extensive immunological workup. Immune cell sub-analysis revealed a reduced CD4+ T helper cell count of 77/μl (normal range: 490–1640/μl) and a decreased CD8+ T suppressor cell count of 52/μl (normal range: 170–880/μl), which were to be expected in patients on fingolimod therapy. Further analysis revealed a normal total IgG level of 817 mg/dl (normal range: 700–1600 mg/dl). The levels of the IgG subclasses IgG1 (550 mg/dl), IgG3 (16.1 mg/dl) and IgG4 (12.2 mg/dl) also were within normal parameters. However, we found an IgG2 deficiency of 108 mg/dl (normal range: 700–1600 mg/dl). The levels of the IgG subclasses IgG1 (550 mg/dl), IgG3 (16.1 mg/dl) and IgG4 (12.2 mg/dl) also were within normal parameters.

**Discussion and conclusion**

Cryptococcal meningoencephalitis accounts for approximately 625,000 deaths per year worldwide. While most cases occur in immunocompromised individuals such as patients with AIDS, cryptococcal meningoencephalitis can also be seen in non-immunocompromised patients [10]. As in our case, Cryptococcus neoformans var. grubii is the causative agent for 95% of infections. After inhalation, cryptococcus disseminates hematogenously with a propensity for the CNS. Clinical symptoms typically include headache, fever, malaise and meningeal irritation. The most common and severe complication is an elevated ICP which occurs in more than 50% of HIV patients [9]. In non-HIV patients this complication is uncommon. Accordingly, our patient had neither clinical nor paraclinical signs of an increased ICP. CSF analysis typically shows lower cells counts in HIV patients (0–50 cells/μL) than in non-HIV patients (20–200 cells/μL). Cryptococcus can be cultured from CSF within 48 to 72 h. The unspecific clinical signs and CSF chemistry often delay diagnosis resulting in an increased morbidity and mortality [11]. Blood cultures are often positive (90%) in HIV positive patients, but rarely in non-HIV patients (21%). Our case is the first report where blood cultures provided the right diagnosis in a fingolimod-treated MS patient. Since blood cultures are simple to obtain and helpful to identify other CNS pathogens, their importance should be emphasised. Detection of cryptococcal antigen in CSF via lateral flow assay has a high sensitivity and specificity of more than 98%, thereby replacing the insensitive india ink staining. Discontinuation of any immunomodulatory medication and initiation of antifungal therapy is mandatory for the successful treatment of cryptococcus meningoencephalitis. Induction therapy with amphotericin B in combination with fluconazole (or fluconazole) for at least 2 weeks is recommended [11–13]. Maintenance treatment and consolidation therapy with fluconazole are advised for at least 1 year. Even though there are no official guidelines, subsequent immunomodulatory MS therapy should include simultaneous lifelong fluconazole prophylaxis. Of note, fingolimod reduces peripheral blood levels of CD4+ and CD8+ T cells by about 80% as also observed in our patient. However, this reduction is selective as targeted cell populations are naïve T cells and central memory T cells while peripheral effector memory T cells, which are key for pathogen clearance, are spared. Fingolimod also decreases the T-cell production of proinflammatory factors such as interferon γ, which is, *inter alia*, important for the defence against fungal pathogens. In addition to that, our patient suffered from an IgG2 deficiency. As this immunological phenomenon has so far not been described as a specific side effect of fingolimod therapy it was possibly a pre-existing condition which had unfortunately not been detected before therapy initiation. IgG2 is the major immunoglobulin subclass directed against polysaccharide antigens such as the cryptococcal capsular polysaccharide glucuronoxylomannan. Accordingly, IgG2 deficiency has been linked to Cryptococcus gattii meningoitis in otherwise healthy non-immunocompromised patients [14]. In summary, as the other 8 cases of cryptococcal meningoencephalitis in patients on fingolimod were either fatal or lead to severe neurological disability we recommend measuring total IgG and in particular IgG2 levels prior to initiation of therapy in order to assess individual risk.

In summary, fever, headache and disorientation in combination with fingolimod-induced lymphopenia should always be considered a red flag for cryptococcosis and should entail lumbar puncture and a cryptococcal antigen test. Blood cultures are a valuable asset. Even though this is only the ninth reported case worldwide it underlines the necessity for constant vigilance in MS patients under immunomodulatory therapy since delayed treatment of cryptococcal meningoencephalitis is associated with increased morbidity and mortality.
Abbreviations
CSF: Cerebrospinal fluid; ICP: Intracranial pressure; RRMS: Relapsing-remitting multiple sclerosis; MS: Multiple sclerosis

Acknowledgements
We would like to thank the German National Reference Centre for Invasive Fungal Infections for the identification of the strain and verification of antifungal susceptibility.

Authors’ contributions
T.W. Conceptualization, Investigation, Writing - Original Draft, Writing - Review & Editing; A.K.M Conceptualization, Investigation, Writing - Original Draft, C.M. Conceptualization, Writing - Review & Editing; C.B. Investigation, Writing - Original Draft; V.W. Investigation, Writing - Original Draft; O.A. Conceptualization, Writing - Review & Editing; H.P.H. Conceptualization, Investigation, Writing - Original Draft, Writing - Review & Editing; D.K. Conceptualization, Investigation, Writing - Original Draft; Writing - Review & Editing; All authors read and approved the final manuscript.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
A written consent has been obtained from the patient for the publication of her course of disease as a case report in a peer-reviewed medical journal.

Competing interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: T.W., A.K.M, C.B., V.W. and C.M. have no disclosures. D.K. received compensation for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, Celgene Receptos, GeNeuro, MedImmune, MedDay, Merck, Novartis, Roche, Sanofi Genzyme and TG Therapeutics with approval by the Rector of Heinrich Heine University. Orhan Aktas has received grant support from Roche, Sanofi Genzyme, and TG Therapeutics with approval by the Rector of Heinrich Heine University. H.-P.H. received compensation for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, Celgene Receptos, GeNeuro, MedImmune, MedDay, Merck, Novartis, Roche, Sanofi Genzyme and TG Therapeutics with approval by the Rector of Heinrich Heine University. A.K.M, C.B., V.W. and C.M. have no disclosures. D.K. received compensation for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, Celgene Receptos, GeNeuro, MedImmune, MedDay, Merck, Novartis, Roche, Sanofi Genzyme and TG Therapeutics with approval by the Rector of Heinrich Heine University. A.K.M, C.B., V.W. and C.M. have no disclosures.

Author details
1Institute of Medical Microbiology and Hospital Hygiene, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.
2Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.

Received: 27 February 2020 Accepted: 21 April 2020
Published online: 27 April 2020

References
1. Achtnichts L, et al. Cryptococcal Meningoencephalitis in a patient with multiple sclerosis treated with Fingolimod. JAMA Neurol. 2015;72(10): 1203–5.
2. Huang D. Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod. Neurology. 2015;85(10):291–322.
3. Grebenciucova E, Reder AT, Bernard JT. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literature. Mult Scler Relat Disord. 2016;9:158–62.
4. Seto H, et al. Disseminated Cryptococcosis in a 63-year-old patient with multiple sclerosis treated with Fingolimod. Intern Med. 2016;55(22):3383–6.
5. Ward MD, Jones DE, Goldman MD. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis. Mult Scler Relat Disord. 2016;9:47–9.
6. Pham C, Bennett I, Jithoo R. Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod. BMJ Case Rep. 2017;2017. https://doi.org/10.1136/bcr-2014-201026.
7. Anene-Maidoh TI, Paschall RM, Graham SR. Refractory cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod: a case report. Interdiscip Neurosurg. 2018;128:9.
8. Chong I, Wang KY, Lincoln CM. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings. Clin Imaging. 2019;54:53–6.
9. Graybill RJ, Sobel JD, Saag MS. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis. 2000;30:47–54.
10. Pappas PG. Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc. 2013;124:61–79.
11. Perfect JR, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50(3):291–322.
12. Pappas PG, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009;48(12):1775–83.
13. Loyse A, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and fluconazole as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2012;54(1):121–8.
14. Marr KA. Cryptococcus gattii as an important fungal pathogen of western North America. Expert Rev Anti-Infect Ther. 2012;10(6):637–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.